Bristol Myers Squibb (BMY) Long-Term Investments (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Long-Term Investments for 17 consecutive years, with $397.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Investments rose 14.74% year-over-year to $397.0 million in Q2 2026; TTM through Jun 2026 was $397.0 million, a 14.74% increase from a year earlier, with the FY2025 full-year figure at $396.0 million, up 23.75% from the prior year.
• Long-Term Investments was $397.0 million for Q2 2026 at Bristol Myers Squibb, up from $366.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $406.0 million in Q3 2025 and troughed at $320.0 million in Q4 2024.
• A 4-year average of $362.5 million and a median of $364.0 million in 2023 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments retreated 12.09% in 2024 and grew 25.31% in 2025, its largest moves.
• Over 4 years, Long-Term Investments stood at $364.0 million in 2023, then fell by 12.09% to $320.0 million in 2024, then increased by 23.75% to $396.0 million in 2025, then advanced by 0.25% to $397.0 million in 2026.
• The last three Long-Term Investments figures came in at $397.0 million (Q2 2026), $366.0 million (Q1 2026), and $396.0 million (Q4 2025), per Business Quant data.